Tech · MIT Technology Review
The U.S. Food and Drug Administration has approved more than 1,300 AI-enabled medical devices
Compiled by KHAO Editorial — aggregated from 1 outlet. See llms.txt for citation guidance.
◌ Single Source
AI applications that do not count as medical devices— for example, those that handle scheduling and administrative tasks—are more difficult to track but are also rapidly increasing.
Key facts
- The U.S. Food and Drug Administration has approved more than 1,300 AI-enabled medical devices, mostly for interpreting diagnostic images
- A recent survey of technology leaders found that 72% said their top priority for AI was reducing caregiver burden and improving caregiver satisfaction, while over half (53%) cited workflow efficiency
- Providers recognize that risk: In the same survey, 77% said immature AI tools are a significant barrier to adoption
- This content was produced by Insights, the custom content arm of MIT Technology Review
Summary
The AI market is full of big promises of grand transformation. The opportunity is genuine, but execution can be difficult. Numerous software vendors have tried to “fix” health care challenges but failed because they misunderstood the environment. AI applications for health care are proliferating rapidly. Any health care-related application can potentially impact patient care, whether directly or indirectly, and AI apps that are poorly designed or inadequately trained and validated can put patients at risk.